"Insights from Industry" is a dynamic series of interviews at the cutting edge of the life sciences industry.
Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible
insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.
While there is still large-scale investment in traditional small molecule pharmaceuticals, the past decade has seen a major shift towards the development of biological molecules for therapeutic purposes.
Many older drugs are well understood from a safety perspective and have often been used successfully off label for other indications.
There are five different ways. The first one is the simplest: they just go with what they already know. It’s the tried and tested methods. They’ll buy from the same suppliers they’ve already bought from, and, if they want to tweak it slightly, then they’ll probably go to them first. It’s just using what they already have.
Microcystins have become the generic name for the toxins produced from blue-green, algae which can bloom in surface water impoundments, slow moving streams and rivers.
Master Bond manufactures a full line of formulations that have been fully tested to meet USP Class VI requirements for both disposable and reusable medical devices.
Bioluminescence is a natural phenomenon in which light is produced by a chemical reaction. It requires an enzyme called luciferase and a substrate called luciferin. These two molecules can be found in diverse species all over the world, such as beetles and fungi but most often in marine animals like jelly fish, deep-sea fish, shrimp and so forth.
AuroLase Therapy utilizes the unique “optical tunability” of a new class of materials developed at Rice University to focus the treatment on the tumor. These AuroShell® particles (also known as nanoshells) can be designed to absorb different wavelengths of...
A blood bank is a place where blood is collected from donors, typed, separated into components, stored and prepared for transfusion to recipients.
Olympus Biotech was established in December 2010 as a wholly owned company of Olympus Corporation. Olympus Biotech is dedicated to the development and distribution of regenerative medicines, an area of increasing importance and optimism.